Addex Therapeutics vs AIM Immunotech
AIM Immunotech is the larger business, with $88,000 of revenue in fiscal 2025 against $36,178 for Addex Therapeutics (2.4 times as much). AIM Immunotech grew faster (-48.2% against -92.1%). AIM Immunotech kept more of each dollar of sales as profit: a net margin of -15861.4% against -22448.4%.
| Latest fiscal year | Addex TherapeuticsADXN, 2025 | AIM ImmunotechAIM, 2025 |
|---|---|---|
| Revenue | $36,178 | $88,000 |
| Revenue growth | -92.1% | -48.2% |
| Net income | −$8.1m | −$14.0m |
| Operating margin | -9390.8% | -13254.5% |
| Net margin | -22448.4% | -15861.4% |
| Return on equity | -97.4% | — |
| Free cash flow | −$2.6m | −$11.0m |
| Cash | $2.1m | $3.0m |
| Total debt | $0 | $8.0m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 19 |
| Market value | $3.7m | $4.7m |
| Price vs our value range | — | — |
| Moat score | — | 5 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 6 buys, 0 sales |